PrEP research: Gilead didn’t infringe patents, ȷury rules

The drug company Gilead Sciences won on all counts in its legal battle with the US government over control of patents for antiviral drugs for the pre-exposure prophylaxis of HIV infection. The six member jury needed little time to return its verdict in a Delaware courtroom on 9 May.Scientists at the US Centers for Disease Control and Prevention had proved that the drug known as Truvada could be effective in preventing HIV infection and filed patents for that use. In 2019 the government sued Gilead for $1bn in royalties on PrEP sales of Truvada associated with use of those patents. But Gilead refused to recognise the patents and countersued to have them voided.1“We are pleased with today’s favourable jury verdict,” said Gilead executive vice president Deb Telman. “The jury determined that Gilead has not infringed the US government’s patents and that the patents are invalid.”But others were not so pleased….
Read Original Article: PrEP research: Gilead didn’t infringe patents, ȷury rules »